ICHORtec and Johns Hopkins Team Up to Advance CRISPR Technology Using Quantum Methods

ICHORtec and Johns Hopkins University Partner to Enhance CRISPR Gene Editing Precision

In a groundbreaking development in molecular medicine, ICHORtec GmbH has announced a significant expansion of its research collaboration with the laboratory of Professor Gregory A. Newby at the Johns Hopkins University School of Medicine. This partnership, which aligns with the International Year of Quantum Science and Technology (IYQ) 2025, aims to employ ICHORtec's proprietary Quantum Fluorimetry of Molecular Binding (Q-FMB®) technology to dramatically improve the specificity of CRISPR gene editing, a technology that has revolutionized genetic engineering.

The Quantum Leap in CRISPR Technology

CRISPR gene editing has been lauded for its potential to transform genetic medicine, enabling precise modifications to DNA. However, a persistent challenge in this field has been the management of off-target effects, which can lead to unintended and potentially harmful changes in the genome. ICHORtec's Q-FMB® technology offers a solution by providing a highly accurate method for designing and evaluating CRISPR guide RNA (gRNA). This advancement minimizes the possibility of off-target edits, thereby enhancing the safety and efficacy of gene editing therapies.

Using advanced quantum mechanics principles, the Q-FMB® system measures free energy changes (ΔG), which is a pivotal factor influencing molecular interactions. This innovative approach directly quantifies the energy dependent on gRNA binding specificity—a crucial aspect for developing more effective CRISPR applications.

A recent study published by ICHORtec in the journal PLOS ONE outlines how the Q-FMB® technology can precisely distinguish between flawless DNA duplexes and those possessing single-nucleotide mismatches, greatly improving the accuracy of molecular editing.

Strengthening the Collaboration

Uwe Korth, CEO of ICHORtec GmbH, expressed enthusiasm over the strengthened partnership with Johns Hopkins University. He stated, "We are excited to enhance our collaboration with Johns Hopkins University, utilizing Quantum FMB® to push the boundaries of CRISPR gene editing precision. This partnership reflects our commitment to applying quantum principles to tackle critical challenges within molecular science. We are pleased that Q-FMB® technology concurrently offers significant cost and time savings while advancing the safety of gene editing processes."

The collaboration not only focuses on CRISPR improvements but also aims to explore diagnostic applications, including rapid tests for Methicillin-Resistant Staphylococcus aureus (MRSA) and Multidrug-Resistant Tuberculosis (MDR-TB). This multifaceted approach showcases the versatility and potential of Q-FMB® technology in addressing serious global health challenges.

About ICHORtec GmbH

Founded in 2020, ICHORtec GmbH operates out of Berlin and Düren, Germany, focusing on the forefront of next-generation molecular science. The company actively collaborates with prestigious institutions such as the Fraunhofer Institute for Applied Polymer Research and benefits from European Union funding through the European Regional Development Fund. With its cutting-edge technology and collaborative initiatives, ICHORtec is poised to play a pivotal role in shaping the future of genetic research and therapies.

As ICHORtec and Johns Hopkins University continue to explore the vast potentials of Q-FMB® technology, the scientific community eagerly anticipates advancements that could revolutionize the landscape of gene therapy, making it safer, more effective, and broader in application. For more information about ICHORtec, visit www.ichortec.com.